Partnership to Find Synergistic Compounds for RNA-Based Anticancer Drugs
Cancer immunotherapeutics firm Ribological inked a compound screening agreement with drug discovery services firm 4SC Discovery and the latter’s protein services subsidiary Crelux, focused on the identification and optimization of anticancer compounds. Ribological is a subsidiary of BioNTech that is developing RNA-based drugs for targeted cancer immunotherapy.
Through the agreement 4SC and Crelux will implement a hit-finding program using 4SC’s in silico screening platform to identify candidate compounds that act synergistically with RNA molecules for cancer immunotherapy. Crelux will apply molecular biological tests for optimizing the compounds using its Intract-MS assays. Ribological will be responsible for carrying out further preclinical testing and potentially clinical trials to evaluate identified compounds in combination with its RNA-based drugs.
“This is the first major joint project that we have launched as part of our new strategic i2c (idea to candidate) cooperation with our partner Crelux,” remarks Daniel Vitt, MD at 4SC Discovery and CSO at parent company 4SC. “As service providers and cooperation partners for biotech and pharma companies, 4SC Discovery and Crelux together can cover both the entire value chain from the idea for a product to the preclinical drug development candidate.”
The i2C platform has been established to offer clients a seamless process from early concept through to preclinical development candidates ready for testing in animal models. Services are available through fee-based agreements, and also through risk-sharing collaborations.